Skip to main content
. 2011 Sep 30;204(11):1711–1722. doi: 10.1093/infdis/jir637

Table 2.

Prevalence, Persistence, and Incidence of Type-Specific Anal Human Papillomavirus Infection Among Men Who Have Sex With Men and Men Who Have Sex With Women in the HPV in Men (HIM) Study, 2005–2009

MSM (n = 156)
MSW (n = 954)
Incident anal infections
Incident anal infections
HPV type Period prevalence, No. (%)a Persistent infection, No. (%)b Men at risk, No. c Men with infection, No. Person-months Incidence rate (95% CI) d Period prevalence, No. (%)a Persistent infection, No. (%)b Men at risk, No. c Men with infection, No. Person-months Incidence rate (95% CI)d IRR (95% CI)
Any HPV 97 (62.2) 50 (32.1) 72 13 502 25.9 (13.8–44.3) 174 (18.2) 40 (4.2) 829 49 6032 8.1 (6.0–10.7) 3.2 (1.7–5.9)
Oncogenic 65 (41.7) 25 (16.0) 107 16 756 21.2 (12.1–34.3) 86 (9.0) 15 (1.6) 892 24 6472 3.7 (2.4–5.5) 5.7 (3.0–10.7)
    16 16 (10.3) 8 (5.1) 145 5 1038 4.8 (1.6–11.2) 26 (2.7) 0 (0.0) 933 5 6782 0.7 (.2–1.7) 6.5 (1.9–22.6)
    18 12 (7.7) 3 (1.9) 148 4 1060 3.8 (1.0–9.7) 8 (0.8) 0 (0.0) 952 6 6916 0.9 (.3–1.9) 4.3 (1.2–15.4)
    31 4 (2.6) 0 (0.0) 153 1 1095 0.9 (.0–5.1) 4 (0.4) 2 (0.2) 951 1 6909 0.1 (.0–.8) 6.3 (.4–100.8)
    33 6 (3.9) 1 (0.6) 152 2 1088 1.8 (.2–6.6) 3 (0.3) 0 (0.0) 952 1 6908 0.1 (.0–.8) 12.7 (1.2–140.0)
    35 7 (4.5) 3 (1.9) 150 1 1067 0.9 (.0–5.2) 1 (0.2) 0 (0.0) 953 0 6922 0.0 -
    39 9 (5.8) 3 (1.9) 148 1 1062 0.9 (.0–5.2) 8 (0.8) 1 (0.1) 951 5 6908 0.7 (.2–1.7) 1.3 (.2–11.1)
    45 8 (5.1) 2 (1.3) 151 3 1076 2.8 (.6–8.1) 5 (0.5) 2 (0.2) 950 1 6904 0.1 (.0–.8) 19.2 (2.0–185.0)
    51 13 (8.3) 4 (2.6) 146 3 1048 2.9 (.6–8.4) 19 (2.0) 4 (0.4) 942 7 6834 1.0 (.4–2.1) 2.8 (.7–10.8)
    52 13 (8.3) 4 (2.6) 150 7 1075 6.5 (2.6–13.4) 6 (0.6) 2 (0.2) 951 3 6909 0.4 (.1–1.3) 15.0 (3.9–58.0)
    56 6 (3.9) 1 (0.6) 151 1 1077 0.9 (.0–5.2) 6 (0.6) 1 (0.1) 949 1 6881 0.1 (.0–.8) 6.4 (.4–102.1)
    58 7 (4.5) 2 (1.3) 152 3 1089 2.8 (.6–8.1) 7 (0.7) 1 (0.1) 950 3 6904 0.4 (.1–1.3) 6.3 (1.3–31.4)
    59 11 (7.1) 1 (0.6) 151 6 1065 5.6 (2.1–12.3) 9 (0.9) 0 (0.0) 946 1 6877 0.1 (.0–.8) 38.7 (4.7–321.8)
    68 5 (3.2) 2 (1.3) 154 3 1101 2.7 (.6–8.0) 4 (0.4) 3 (0.3) 951 1 6910 0.1 (.0–.8) 18.8 (2.0–181.0)
Non-oncogenic 85 (54.5) 39 (25.0) 86 15 615 24.4 (13.7–40.2) 119 (12.5) 29 (3.0) 875 40 6360 6.3 (4.5–8.6) 3.9 (2.1–7.0)
    06 18 (11.5) 8 (5.1) 141 3 1012 3.0 (.6–8.7) 25 (2.6) 4 (0.4) 935 6 6800 0.9 (.3–1.9) 3.4 (.8–13.4)
    11 7 (4.5) 3 (1.9) 151 2 1079 1.9 (.2–6.7) 2 (0.2) 0 (0.0) 953 1 6922 0.1 (.0–.8) 12.8 (1.2–141.6)
    26 1 (0.6) 0 (0.0) 155 0 1109 0.0 - 0 (0.0) 0 (0.0) 954 0 6929 0.0 -
    40 3 (1.9) 0 (0.0) 153 0 1095 0.0 - 0 (0.0) 0 (0.0) 954 0 6929 0.0 -
    42 5 (3.2) 0 (0.0) 155 4 1109 3.6 (1.0–9.2) 3 (0.3) 1 (0.1) 952 1 6906 0.1 (.0–.8) 24.9 (2.8–222.9)
    53 18 (11.5) 5 (3.2) 143 5 1018 4.9 (1.6–11.5) 13 (1.4) 3 (0.3) 946 5 6865 0.7 (.2–1.7) 6.7 (2.0–23.3)
    54 8 (5.1) 2 (1.3) 150 2 1075 1.9 (.2–6.7) 7 (0.7) 2 (0.2) 951 4 6908 0.6 (.2–1.5) 3.2 (.6–17.5)
    55e 5 (3.2) 2 (1.3) 153 2 1092 1.8 (.2–6.6) 3 (0.3) 1 (0.1) 953 2 6923 0.3 (.0–1.0) 6.3 (.9–45.0)
    61 11 (7.1) 6 (3.9) 147 2 1051 1.9 (.2–6.9) 15 (1.6) 5 (0.5) 944 5 6957 0.7 (.2–1.7) 2.6 (.5–13.5)
    62 8 (5.1) 2 (1.3) 151 3 1081 2.8 (.6–8.1) 22 (2.3) 6 (0.6) 940 8 6825 1.2 (.5–2.3) 2.4 (.6–8.9)
    64e 1 (0.6) 0 (0.0) 156 1 1115 0.9 (.0–5.0) 0 (0.0) 0 (0.0) 954 0 6929 0.0 -
    66 5 (3.2) 1 (1.3) 152 1 1083 0.9 (.0–5.1) 9 (0.9) 2 (0.2) 948 3 6881 0.4 (.1–1.3) 2.1 (.2–20.4)
    67 3 (1.9) 0 (0.0) 154 1 1101 0.9 (.0–5.1) 1 (0.1) 0 (0.0) 953 0 6921 0.0 -
    69 2 (1.3) 0 (0.0) 154 0 1102 0.0 - 0 (0.0) 0 (0.0) 954 0 6929 0.0 -
    70 14 (9.0) 3 (1.9) 148 6 1060 5.7 (2.1–12.3) 4 (0.4) 0 (0.0) 952 2 6917 0.3 (.0–1.0) 19.6 (4.0–97.0)
    71 8 (5.1) 4 (2.6) 150 2 1073 1.9 (.2–6.7) 5 (0.5) 2 (0.2) 949 0 6896 0.0 -
    72 7 (4.5) 0 (0.0) 155 6 1108 5.4 (2.0–11.8) 4 (0.4) 0 (0.0) 951 1 6910 0.1 (.0–.8) 37.4 (4.5–310.6)
    73 16 (10.3) 5 (3.2) 146 6 1042 5.8 (2.1–12.5) 2 (0.2) 0 (0.0) 952 0 6915 0.0 -
    81 9 (5.8) 4 (2.6) 150 3 1068 2.8 (.6–8.2) 6 (0.6) 3 (0.3) 949 1 6884 0.1 (.0–.8) 19.3 (2.0–185.8)
    82 5 (3.2) 1 (0.6) 152 1 1087 0.9 (.0–5.1) 1 (0.1) 0 (0.0) 954 1 6929 0.1 (.0–.8) 6.4 (.4–101.9)
    83 7 (4.5) 0 (0.0) 151 2 1065 1.9 (.2–6.8) 5 (0.5) 0 (0.0) 950 1 6902 0.1 (.0–.8) 13.0 (1.2–143.0)
    84 22 (14.1) 6 (3.9) 140 6 1000 6.0 (2.2–13.1) 14 (1.5) 1 (0.1) 947 7 6881 1.0 (.4–2.1) 5.9 (2.0–17.6)
    89e 17 (10.9) 3 (1.9) 148 9 1057 8.5 (3.9–16.2) 14 (1.5) 3 (0.3) 943 3 6848 0.4 (.1–1.3) 19.4 (5.3–71.8)
    IS39e 3 (1.9) 1 (0.6) 154 1 1102 0.9 (.0–5.1) 0 (0.0) 0 (0.0) 954 0 6929 0.0 -

Abbreviations: CI, confidence interval; HPV, human papillomavirus; IRR, incidence rate ratio; MSM, men who have sex with men; MSW, men who have sex with women.

a

The number and proportion of men with type-specific infection at either enrollment or the 6-month visit.

b

The number and proportion of men with type-specific infection at both enrollment and the 6-month visit.

c

The number of men negative for a specific type at enrollment.

d

The number of infections per 1000 person-months.

e

HPV-55 is considered a subtype of HPV-44; HPV-64 is considered a subtype of HPV-34; IS39 is considered a subtype of HPV-82; HPV-89, previously CP6108.